Novel Monoclonal Antibody Therapy in a Patient With Treatment-Refractory Warm Autoimmune Hemolytic Anemia.
| Autor: | Tahhan F; Department of Internal Medicine, Adventist Health White Memorial, Los Angeles, USA., Huynh B; Department of Internal Medicine, Adventist Health White Memorial, Los Angeles, USA., Xu P; Department of Pharmacy Services, Adventist Health White Memorial, Los Angeles, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2022 Jun 17; Vol. 14 (6), pp. e26051. Date of Electronic Publication: 2022 Jun 17 (Print Publication: 2022). |
| DOI: | 10.7759/cureus.26051 |
| Abstrakt: | In autoimmune hemolytic anemia (AIHA), hemolysis is the hallmark symptom. Cold agglutinin disease (CAD) and warm autoimmune hemolytic anemia (wAIHA) are the two major forms of AIHA. Hemolysis is complement dependent in CAD, whereas wAIHA is a partially complement-mediated disorder. At the time of writing, sutimlimab-jome is the only FDA-approved monoclonal antibody in the treatment of CAD. In a case of severe treatment-refractory wAIHA, a two-week course with sutimlimab-jome resulted in a sustained decrease in total bilirubin level and a notable reduction in transfusion requirement, suggesting that it is also effective in the treatment of wAIHA. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Tahhan et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|